QUOTE AND NEWS
FiercePharma  Sep 26  Comment 
Novo Nordisk has made it official: The Danish drugmaker is making a full-fledged go at obesity R&D, looking to build a Seattle hub and hire some investigators as it expands its research palate.
FierceBiotech  Sep 25  Comment 
Novo Nordisk has made it official: The Danish drugmaker is making a full-fledged go at obesity R&D, looking to build a Seattle hub and hire up some investigators as it expands its research palate.
Motley Fool  Sep 25  Comment 
Three reasons make Novo Nordisk a must-have company in your stock portfolio.
SeekingAlpha  Sep 23  Comment 
By Hebba Investments: Introduction When investors look for speculative exploration companies to invest in they need to make sure that the reward is worth the risk - because there is A LOT of risk in these companies. Gold is extremely hard to...
SeekingAlpha  Sep 23  Comment 
By Antonio Carradinha: The division of Banco Espirito Santo in BES (OTCPK:BKESY) - "bad bank" - and Novo Banco - "good bank" - was analyzed in my previous article. In practice, what was the largest Portuguese private bank became only a simple...
FiercePharma  Sep 19  Comment 
Novo Nordisk is hustling to get work done so that it can resubmit its blockbuster hopeful Tresiba to the FDA next year with an eye on getting into the market by 2016, three years after the FDA squelched its plans with its initial denial. In the...
FierceBiotech  Sep 19  Comment 
Novo Nordisk picked up European approval for a combination of a long-acting insulin and its own Victoza, pioneering a once-a-day approach to Type 2 diabetes that could bring in blockbuster sales.
FiercePharma  Sep 17  Comment 
Analysts have been waiting--and waiting--for drugmakers to realize the growth they've predicted for the obesity market. And with a couple of pharma companies preparing to pony up R&D and marketing resources for their obesity products, it could...
FierceBiotech  Sep 17  Comment 
In the midst of its first major foray into treating obesity, Novo Nordisk is liking what it sees in the space, and now the Danish giant plans to hire hundreds of researchers in a gambit to develop new treatments for the global scourge.





You may also be interested in articles related to Novo Nordisk A/S (NVO):
 




References

Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki